Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqGM:PRE
Prenetics Global Full Year 2022 Earnings: Misses Expectations
Prenetics Global (NASDAQ:PRE) Full Year 2022 Results
Key Financial Results
- Revenue: US$275.8m (flat on FY 2021).
- Net loss: US$190.5m (loss widened by 9.5% from FY 2021).
- US$2.51 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Prenetics Global Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 4.2%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 8.6% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Prenetics Global that you should be aware of.
What are the risks and opportunities for Prenetics Global?
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company.
Rewards
Earnings are forecast to grow 122.16% per year
Risks
Volatile share price over the past 3 months
Further research on
Prenetics Global
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.